GSK says new data back malaria treatment (Reuters)


Reuters - GlaxoSmithKline Plc said on Wednesday
clinical results confirmed the benefits of its CDA treatment
for drug-resistant malaria and that it was planning final Phase
III trials to confirm its safety and efficacy.